Skip to main content

  • Home
  • About Us
    • Company Summary
    • Regeneus Strategy
    • Senior Management
    • The Board
    • Corporate Governance
      • Board Charter
      • Audit & Risk
      • Remuneration & Nominations
      • Code of Conduct
      • Continuous Disclosure
      • Risk Management
      • Shareholder Communication
      • Securities Trading
      • Board & Executive Evaluation
      • Diversity
  • Therapeutic Areas
  • Technology
    • MSCs
    • Immunotherapy
    • Cell Secretions
  • Product Pipeline
    • Pipeline Overview
    • Human Health
      • Progenza
      • Human Cancer Vaccine
      • Cell Secretions
    • Animal Health
      • CryoShot Canine
      • Kvax
    • Trials
  • Investors
    • ASX announcements
    • Financials
    • Analyst Coverage
    • Events & Presentations
    • Investor Relations Contact
    • Subscribe
  • News
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
  • Contact
  • Home
  • About Us
    • Company Summary
    • Regeneus Strategy
    • Senior Management
    • The Board
    • Corporate Governance
  • Therapeutic Areas
  • Technology
    • MSCs
    • Immunotherapy
    • Cell Secretions
  • Product Pipeline
    • Pipeline Overview
    • Human Health
    • Animal Health
    • Trials
  • Investors
    • ASX announcements
    • Financials
    • Analyst Coverage
    • Events & Presentations
    • Investor Relations Contact
    • Subscribe
  • News
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
  • Contact
  1. Home
  2. About
  3. News
  4. Article

Regeneus Q2 2017 News Update

Wednesday, 5 July 2017

Regeneus released our Q2 2017 update newsletter designed to keep our investors and followers of the company up to date with all the company and industry news over the last quarter.

View the Q2 newsletter

Click here if you would like to subscribe to receive Regeneus announcements and updates as they are released

Share
  • All results
  • Next
  • Previous
© 2017 Regeneus Ltd | Privacy | Terms of Service